Having trouble viewing this email? View the online version.
ISSM logo

Latest News from the ISSM - July 3, 2020 Member Login
Dr. Alan Shindel Named Editor of Sexual Medicine

Dr. Alan Shindel will become the next editor-in-chief of Sexual Medicine, the ISSM's open access journal. 

Dr. Shindel is a graduate of Washington University Medical School in St. Louis, Missouri, USA. His current practice focuses on the management of sexual health concerns, such as erectile dysfunction (ED), low sexual desire, and Peyronie's disease. 

He was also Sexual Medicine's first editor-in-chief, taking the helm from 2012 to 2015. 

The ISSM would like to thank the journal's current editor-in-chief, Prof. Kwangsung Park, for his valuable work.

Read more about Dr. Shindel and the editorial transition here. 

ISSM University Modules Now Available | Open Access Through September 1st

We're pleased to announce that the first 8 modules of the ISSM curriculum are now available at ISSM University. 

This curriculum includes access to ISSM certified online courses designed to expand healthcare providers' knowledge of sexual medicine. 

The following modules are now online: 

Age-associated Sexual Dysfunctions in Women
by Stephanie S. Faubion

Erectile Dysfunction Surgical Treatment – Penile Prosthesis
by Javier Romero-Otero, Manuel Alonso-Isa & Borja García-Gomez

Mental Health Aspects of Male Sexual Dysfunction
by Rose Hartzell-Cushanick

Peyronie’s Disease
by Georgios Hatzichristodoulou

Premature Ejaculation
by Ege Can Serefoglu

Sexual Dysfunction Emergencies: Priapism, Penile Fracture
by Arthur L. (Bud) Burnett

Testosterone Deficiency in Men
by Mohit Khera

Transgender Hormone Therapy
by Vin Tangpricha

More topics will be added in the coming months.

In addition, access to ISSM University will be open to all users through September 1, 2020.  ISSM members may log in with their usual credentials. Others may request a guest account or join the ISSM.

Learn more about ISSM University.

Sildenafil a Popular Choice for Men with ED

Sildenafil was the most frequently-prescribed phosphodiesterase type 5 inhibitor for erectile dysfunction (ED) over a five-year period, researchers report. 

Their findings, published online in March in the Journal of Sexual Medicine, are based on data from over 100,000 men in the United States between 2010 and 2015.

Three ED drugs were studied: sildenafil, tadalafil, and vardenafil. 

More details on the study, including information on the men's drug switching patterns, can be found here. 

You are receiving this newsletter because you are subscribed to our mailing list.
If you would rather not receive emails like this in the future you can unsubscribe.

ISSM | International Society for Sexual Medicine
P.O. Box 94 | 1520 AB Wormerveer | The Netherlands